Tafenoquine Succinate is used for preventing malaria in adults through a three-phase dosing regimen. It was first introduced by Glaxosmithkline Intellectual Property Development Ltd England in its drug Krintafel on Jul 20, 2018. Another drug containing Tafenoquine Succinate is Arakoda. 2 different companies have introduced drugs containing Tafenoquine Succinate.

Tafenoquine Succinate Patents

Given below is the list of patents protecting Tafenoquine Succinate, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Arakoda	US10342791	Regimens of tafenoquine for prevention of malaria in malaria-naive subjects	Dec 02, 2035	60 Degrees Pharms
Arakoda	US10888558	Regimens of tafenoquine for prevention of malaria in malaria-naive subjects	Dec 02, 2035	60 Degrees Pharms
Arakoda	US11744828	Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects	Dec 02, 2035	60 Degrees Pharms

Add above patents to watchlist

Tafenoquine Succinate's Family Patents

Full family tree